Fuction and Application of Niraparib

Niraparib  is an orally active small molecule PARP inhibitor developed by Tesaro to treat ovarian cancer..
The drug is approved by the US FDA for the maintenance treatment of adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy.

Strenghths of Our Products:
 
1) Living with chemical innovation;
2) Equipped with the professional quality testing equipment & conscience of the field.
3) Most competitive price and mostly welcomed by foreign customers from North America, Europe, the Middle East, etc.
4) Highly pure and salfe and can be applied in various fields.